Antimullerian hormone (AMH) and age as predictors of preimplantation genetic testing for aneuploidies (PGT-A) cycle outcomes and blastocyst quality on day 5 in women undergoing in vitro fertilization (IVF)

被引:4
|
作者
Arnanz, A. [1 ,2 ,3 ,4 ]
Bayram, A. [1 ,2 ]
Elkhatib, I. [1 ,2 ]
Abdala, A. [1 ,2 ]
El-Damen, A. [1 ,2 ]
Patel, R. [1 ,2 ]
Lawrenz, B. [1 ,2 ,5 ]
Melado, L. [1 ,2 ]
Fatemi, H. [1 ,2 ]
De Munck, N. [6 ]
机构
[1] ART Fertil Clin Abu Dhabi & Dubai, Embryol Lab, Dubai, U Arab Emirates
[2] IVF Clin, Dubai, U Arab Emirates
[3] Univ Alcala de Henares, Biomed & Biotechnol Dept, Madrid, Spain
[4] IVIRMA, Embryol Lab, Madrid, Spain
[5] Womens Univ Hosp Tuebingen, Obstetr Dept, Tubingen, Germany
[6] UZ Brussels, Jette, Belgium
关键词
PGT-A; AMH; Age; Euploid rate; Blastocyst quality; ANTI-MULLERIAN HORMONE; CONTROLLED OVARIAN STIMULATION; ANTRAL FOLLICLE COUNT; EMBRYO QUALITY; OOCYTE QUALITY; MLLERIAN HORMONE; SERUM-LEVELS; MARKER; RESERVE; PREGNANCY;
D O I
10.1007/s10815-023-02805-z
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Purpose The objective of this study was to investigate whether women with diminished ovarian reserve who planned for PGT-A exhibit a lower number of blastocysts for biopsy, ploidy outcomes, and blastocyst quality on day 5, regardless of age. Methods A retrospective analysis was performed between March 2017 and July 2020 at ART Fertility Clinics Abu Dhabi, including couples that were triggered for final oocyte maturation in an ovarian stimulated cycle planned for PGT-A. Patients were stratified into four AMH groups: < 0.65 ng/ml, 0.65-1.29 ng/ml, 1.3-6.25 ng/ml, and > 6.25 ng/ml; four age categories: <= 30, 31-35, 36-40, and > 40 years. Main results and the role of chance A total of 1410 couples with a mean maternal age of 35.2 +/- 6.4 years and AMH of 2.7 +/- 2.6 ng/ml were included. In a multivariate logistic regression analysis, controlling for age, the chance of having at least one blastocyst biopsied/stimulated cycle (1156/1410), the chance of having at least one euploid blastocyst/stimulated cycle (880/1410), and the chance of having one euploid blastocyst once biopsy was performed (880/1156) were affected in all patients with AMH < 0.65 ng/ml [AdjOR 0.18[0.11-0.31] p = 0.008)], [AdjOR 0.18 [0.11-0.29] p < 0.001], and [AdjOR 0.34 [0.19-0.61] p = 0.015] as well as in patients with AMH 0.65-1.29 ng/ml (AdjOR 0.52 [0.32-0.84] p < 0.001), (AdjOR 0.49 [0.33-0.72] p < 0.001), and (AdjOR 0.57 [0.36-0.90] p < 0.001), respectively. In a multivariate linear regression analysis, AMH values did not affect blastocyst quality (- 0.72 [- 1.03 to - 0.41] p < 0.001). Conclusion Irrespective of age, patients with diminished ovarian reserve (AMH < 1.3 ng/ml) have a lower chance of having at least one blastocyst biopsied and lower chance of having at least one euploid blastocyst per ovarian stimulated cycle. Blastocyst quality was not affected by AMH values.
引用
收藏
页码:1467 / 1477
页数:11
相关论文
共 29 条
  • [21] PREDICTIVE POWER OF ANTI-MULLERIAN HORMONE (AMH) FOR IN VITRO FERTILIZATION (IVF) CYCLE OUTCOMES IN WOMEN WITH SEVERE DIMINISHED OVARIAN RESERVE (DOR)
    Kudesia, R.
    Berger, D. S.
    Zapantis, A.
    Jindal, S. K.
    Pollack, S. E.
    FERTILITY AND STERILITY, 2013, 100 (03) : S503 - S503
  • [22] ASSESSMENT OF DAY 5 MORPHOLOGY GRADING AND METABOLOMIC VIABILITY SCORE AS PREDICTORS OF IMPLANTATION OUTCOME IN WOMEN UNDERGOING IN VITRO FERTILIZATION (IVF).
    Seli, E.
    Botros, L. D.
    Henson, M. A.
    Judge, K. H.
    Sakkas, D. H.
    FERTILITY AND STERILITY, 2010, 94 (04) : S26 - S27
  • [23] Growth hormone supplementation ameliorates blastocyst euploidy rates and improves pregnancy outcomes in women undergoing preimplantation genetic testing for aneuploidy cycles
    Guo, Qingqing
    Liu, Peihao
    Zhou, Wei
    Xia, Mingdi
    Li, Jing
    Lu, Juanjuan
    Ma, Jin-Long
    Chen, Zi-Jiang
    Yan, Junhao
    FRONTIERS IN ENDOCRINOLOGY, 2023, 14
  • [24] Early pregnancy outcomes associated with age and AMH following Next-Generation Sequencing(NGS)-based Preimplantation Genetic Testing for Aneuploidy(PGT-A) in single euploid embryo transfers for advanced age patients
    Kim, Y. I.
    Yang, N. R.
    Han, S. J.
    Kim, J. H.
    Yu, E. J.
    Hur, Y. J.
    Kim, M. J.
    Kang, K. Y.
    Park, E. A.
    Lee, H. C.
    Kim, H. O.
    Kim, Y. S.
    Yoon, T. K.
    HUMAN REPRODUCTION, 2024, 39 : I450 - I450
  • [25] DOES INTRACYTOPLASMIC SPERM INJECTION (ICSI) PROVIDE ANY BENEFIT OVER IN VITRO FERTILIZATION (IVF) ON PREGNANCY OUTCOMES IN NON-MALE FACTOR INFERTILITY CYCLES UNDERGOING PRE-IMPLANTATION GENETIC TESTING FOR ANEUPLOIDY (PGT-A)?.
    Tozour, Jessica N.
    Brady, Alyson
    Akerman, Meredith
    Arnott, Alicia J.
    Sung, Linda
    Fritz, Rani
    FERTILITY AND STERILITY, 2020, 114 (03) : E312 - E313
  • [26] DAY-5 VERSUS DAY-6 BLASTOCYST TRANSFER IN WOMEN UNDERGOING FRESH EMBRYO TRANSFER FOLLOWING IN VITRO FERTILIZATION: DO PREGNANCY OUTCOMES DIFFER?
    Cook, H. M.
    DeUgarte, C. M.
    Mazmanian, G.
    Chacon, R.
    Jordan, B.
    Sahakian, V.
    FERTILITY AND STERILITY, 2010, 94 (04) : S172 - S172
  • [27] Effects of trigger-day progesterone in the preimplantation genetic testing cycle on the embryo quality and pregnancy outcomes of the subsequent first frozen-thawed blastocyst transfer
    Li, Jingdi
    Cui, Yueyue
    Shi, Hao
    Bu, Zhiqin
    Wang, Fang
    Sun, Bo
    Zhang, Yile
    FRONTIERS IN ENDOCRINOLOGY, 2023, 14
  • [28] A pilot study to identify Single Nucleotide Variants (SNVs) as predictors of oocyte/embryo quality in fertile women undergoing Preimplantation Genetic Testing for Monogenic Disorders (PGT-M)
    Kakourou, G.
    Mamas, T.
    Vrettou, C.
    Tsorva, E.
    Zacharia, S.
    Oraiopoulou, C.
    Chatzi, E.
    Kourkouni, E.
    Kourlaba, G.
    Christopikou, D.
    Mastrominas, M.
    Moysidou, M.
    Chatziparasidou, A.
    Georgiou, I.
    Traeger-Synodinos, J.
    HUMAN REPRODUCTION, 2020, 35 : I371 - I371
  • [29] INTRACYTOPLASMIC SPERM INJECTION (ICSI) DOES NOT PROVIDE ANY BENEFIT OVER IN VITRO FERTILIZATION (IVF) ON PLOIDY RATES IN NON-MALE FACTOR INFERTILITY CYCLES UNDERGOING PRE-IMPLANTATION GENETIC TESTING FOR ANEUPLOIDY (PGT-A).
    Tozour, Jessica N.
    Brady, Alyson
    Akerman, Meredith
    Arnott, Alicia J.
    Sung, Linda
    Fritz, Rani
    FERTILITY AND STERILITY, 2020, 114 (03) : E7 - E7